IDH2 and intrahepatic cholangiocarcinoma: In contrast, Jiao et al. demonstrated in a study of 32 patients with ICC that IDH mutations confer a worse prognosis when compared to those with IDH wild-type (3-year OS 33% vs. 81%; P = 0.003) [24].